What biomarker testing is recommended for metastatic Lymphoma

Biomarker Testing for Metastatic Lymphoma

I'd be happy to explain the biomarker testing approach for metastatic lymphoma. However, the specific tests recommended depend on which type of lymphoma you have, since different lymphoma subtypes have different testing needs.

General Biomarker Testing Framework

According to the NCCN Guidelines for Patients, biomarker and genetic testing is a standard part of lymphoma evaluation. Here's what doctors typically look for:

What Biomarker Testing Does

Biomarker testing examines the cancer cells themselves to identify specific mutations or genetic changes. These findings help your oncology team:

• Confirm the exact type of lymphoma
• Identify which treatments might work best (targeted therapies)
• Detect mutations that could affect treatment response
• Monitor for new mutations that might develop during or after treatment

Types of Genetic Changes Tested

According to NCCN Guidelines, lymphoma cells can have various changes including:

• Deletions – when part of a gene or chromosome is missing
• Translocations – when parts of chromosomes switch places (also called rearrangements at the gene level)
• Amplifications – when genes are duplicated or increased
• Point mutations – when specific parts of genes are altered

Common Biomarkers by Lymphoma Type

For B-cell lymphomas (the most common type), testing typically includes:

• CD19, CD20 – markers that help identify B-cell lymphomas and guide CAR T-cell therapy eligibility
• BCL2, BCL6, CD10 – markers that help classify specific subtypes like follicular lymphoma
• TP53, MYC – mutations associated with aggressive disease

For specific subtypes:

• Follicular Lymphoma: CD10+, BCL2+, CD20+, BCL6+ (according to NCCN Guidelines for Follicular Lymphoma)
• Marginal Zone Lymphoma: Testing for specific mutations that may respond to targeted therapies
• DLBCL (Diffuse Large B-Cell Lymphoma): TP53, MYC, BCL2 status; cell-of-origin classification

Emerging Testing: Molecular Residual Disease (MRD)

An important newer test is ctDNA-based MRD testing (circulating tumor DNA). According to recent NCCN Guidelines for B-Cell Lymphomas (December 2024), this blood test can:

• Detect remaining cancer cells after treatment using highly sensitive methods
• Identify molecular recurrence approximately 6-7 months earlier than PET/CT imaging
• Guide decisions about surveillance schedules and additional therapy

Important Next Steps for YOUR Situation

Since biomarker recommendations vary significantly by lymphoma subtype and stage, here are key questions to ask your oncology team:

1. "What specific type of lymphoma do I have, and what biomarker panel is recommended for my subtype?"
2. "Which of these biomarkers will affect my treatment options?"
3. "Should I have MRD (molecular residual disease) testing, and if so, when?"
4. "Are there any mutations in my cancer that make me eligible for targeted therapies or clinical trials?"
5. "Will you retest for biomarkers if my cancer progresses or doesn't respond as expected?"

Why This Matters

Biomarker testing is increasingly important because it can identify patients who benefit from specific targeted treatments—like CAR T-cell therapy for CD19+ B-cell lymphomas or other precision medicine approaches. Your doctor uses these results to personalize your treatment plan.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources: NCCN Guidelines for Patients: Marginal Zone Lymphomas (2024); NCCN Guidelines for Patients: Follicular Lymphoma (2024); NCCN Guidelines for Patients: Diffuse Large B-Cell Lymphomas (2025); NCCN Guidelines for B-Cell Lymphomas (December 2024)